Thiazolidinediones and cardiovascular outcomes in type 2 diabetes Reply

被引：0
|
作者：
Singh, S. [1 ]
Furberg, C. D. [1 ]
机构：
[1] Wake Forest Univ, Winston Salem, NC 27109 USA
来源：
HEART | 2009年 / 95卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：332 / 332
页数：1
相关论文
共 50 条
  • [41] Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus
    Kapoor, Karan
    George, Praveen
    Miller, Michael
    CARDIOLOGY, 2016, 135 (02) : 108 - 126
  • [42] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Zinman, Bernard
    Wanner, Christoph
    Lachin, John M.
    Fitchett, David
    Bluhmki, Erich
    Hantel, Stefan
    Mattheus, Michaela
    Devins, Theresa
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22): : 2117 - 2128
  • [43] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Marso, Steven P.
    Bain, Stephen C.
    Consoli, Agostino
    Eliaschewitz, Freddy G.
    Jodar, Esteban
    Leiter, Lawrence A.
    Lingvay, Ildiko
    Rosenstock, Julio
    Seufert, Jochen
    Warren, Mark L.
    Woo, Vincent
    Hansen, Oluf
    Holst, Anders G.
    Pettersson, Jonas
    Vilsboll, Tina
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19): : 1834 - 1844
  • [44] Cardiovascular Outcomes with Dapagliflozin for Patients with Type 2 Diabetes
    Pavlicek, Vojtech
    DIABETOLOGE, 2019, 15 (03): : 262 - 264
  • [45] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Leitner, H.
    AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2016, 9 (01): : 22 - 22
  • [46] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Leitner, H.
    JOURNAL FUR KARDIOLOGIE, 2016, 23 (1-2): : 54 - 54
  • [47] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Ipp, Eli
    Genter, Pauline
    Childress, Kristin
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (09): : 890 - 891
  • [48] Cardiovascular Outcomes of New Medications for Type 2 Diabetes
    Trujillo, Jennifer M.
    Wettergreen, Sara A.
    Nuffer, Wesley A.
    Ellis, Samuel L.
    McDermott, Michael T.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 (12) : 749 - 758
  • [49] Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes
    Al-Bazz, Dalai Y.
    Wilding, John P. H.
    FUTURE CARDIOLOGY, 2020, 16 (02) : 77 - 88
  • [50] Liraglutide and Renal Outcomes in Type 2 Diabetes REPLY
    Mann, Johannes F. E.
    Orsted, David D.
    Buse, John B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (22): : 2197 - 2198
12345